InsidersTradesSigma
Track the Pulse Biosciences, INC. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Pulse Biosciences, INC. has logged 61 insider filings. Market capitalisation: €3.4bn. The latest transaction was reported on 28 August 2026 (Acquisition). Among the most active insiders: DUGGAN ROBERT W. The full history is free.
61
Insider Decl.
n/a
Thresholds
€121m
23 ops.
Buy Volume
€1m
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Pulse Biosciences, INC. Strong Buy (bullish), based on 4 analysts. Average price target: US$45.25.
37Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,627 of 29,055 companies
15.7
score / 100
Value29
Quality2
FCF yld-1.6%
Earn yld-2.1%
EV/EBITDA·
ROE-78%
Gross mgn-54%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 August 2026
Declarations61 total
1,036 shares@ US$48.235Common StockSEC:0001437749-26-029233:0
Canonical exit: 24 Nov 2026 (T+90)
1,034 shares@ US$48.35Common StockSEC:0001437749-26-029233:1
Canonical exit: 26 Nov 2026 (T+90)
660,233 shares@ US$19.690.39% mcap10.4% of flowCommon StockSEC:0001437749-26-017478:0
Canonical exit: 9 Aug 2026 (T+90)
5,000 shares@ US$1.534.8% of flowCommon StockSEC:0001437749-26-005144:0
20,000 shares@ US$1.530.0009% mcap22.3% of flowCommon StockSEC:0001437749-26-004438:0
20,000 shares@ US$1.530.0009% mcap22.4% of flowCommon StockSEC:0001437749-26-003840:0
4,600 shares@ US$1.530.0002% mcap5.2% of flowCommon StockSEC:0001437749-25-030665:0
20,000 shares@ US$1.5320.4% of flowCommon StockSEC:0001437749-25-029646:0
25,000 shares@ US$4.0020.6% of flowCommon StockSEC:0001437749-25-029432:0
25,000 shares@ US$4.0026.2% of flowCommon StockSEC:0001437749-25-029104:0
34,659 shares@ US$14.660.2% of flowCommon StockSEC:0001437749-25-028988:0
Canonical exit: 9 Dec 2025 (T+90)
15,000 shares@ US$16.400.0076% mcap50.0% of flowCommon StockSEC:0001437749-25-020563:0
30,121 shares@ US$11.0046.3% of flowCommon StockSEC:0001437749-25-003449:0
50,000 shares@ US$17.4290.7% of flowCommon StockSEC:0001437749-24-038145:0
5,187,824 shares@ US$11.0022.7% of flowCommon StockSEC:0000950170-24-138177:0
55,256 shares@ US$17.180.4% of flowCommon StockSEC:0001437749-24-037766:0
Canonical exit: 13 Mar 2025 (T+90)
45,404 shares@ US$17.130.3% of flowCommon StockSEC:0000950170-24-136901:0
Canonical exit: 12 Mar 2025 (T+90)
6,054 shares@ US$16.740.0% of flowCommon StockSEC:0001437749-24-037509:0
Canonical exit: 11 Mar 2025 (T+90)
3,000 shares@ US$11.0031.3% of flowCommon StockSEC:0001437749-24-030292:0
543 shares@ US$11.000.6% of flowCommon StockSEC:0001437749-24-023232:0
650 sharesCommon StockSEC:0001437749-24-022356:0
60,242 sharesCommon StockSEC:0001437749-24-022360:0
5,187,824 sharesCommon StockSEC:0001437749-24-022358:0
3,000 sharesCommon StockSEC:0001437749-24-022341:0
1,086 sharesCommon StockSEC:0001437749-24-022339:0
25 of 61 declarations
关于 Pulse Biosciences, INC.
Pulse Biosciences, Inc. 是一家总部位于美国的医疗技术和生物电医学公司，在纳斯达克市场上市，股票代码为PLSE。该公司专注于非热消融技术，并以其专有的nPulse™平台为核心，该平台使用纳秒脉冲电场消融（nsPFA™）能量，旨在提供极短的电脉冲，以靶向细胞同时保留邻近的非细胞组织。在投资者材料和公司文件中，Pulse Biosciences 将自己定位为在当前治疗方案不完整或不理想的领域开发新型治疗解决方案的公司。（[investors.pulsebiosciences.com](https://investors.pulsebiosciences.com/?utm_source=openai)） 该公司成立于2014年，前身为Electroblate, Inc.，并于2015年12月更名为Pulse Biosciences, Inc.。这一公司转型反映了从早期技术开发商向临床阶段医疗技术平台公司更广泛的战略演变。随着时间的推移，该业务已将其重点放在更高价值的医疗保健应用上，特别是心房颤动，同时仍在其他软组织消融应用中保持选择性。（[stockanalysis.com](https://stockanalysis.com/stocks/plse/company/?utm_source=openai)） Pulse Biosciences 的产品组合以多个nPulse品牌系统为中心。该公司将其CellFX系统描述为基于纳米脉冲刺激（NPS™）技术的首个商业产品。除此之外，该公司还在推进nPulse Vybrance经皮电极系统、nPulse心脏外科钳、nPulse心脏导管系统和nPulse控制台平台。这些项目共同表明，其战略是从皮肤病学或软组织应用扩展到心脏电生理学，在心脏电生理学领域，临床和商业机会更大，但从监管和执行角度来看也更具挑战性。（[investors.pulsebiosciences.com](https://investors.pulsebiosciences.com/?utm_source=openai)） 从竞争角度来看，Pulse Biosciences 在一个由大型医疗设备公司和成熟的电生理学参与者主导的领域中占据着利基地位。其主要区别在于其专利的nsPFA机制、非热方法以及广泛的知识产权组合。该公司认为，与传统的消融方法相比，这些特性可以提高安全性，保留周围组织，并可能支持更好的手术结果。对于投资者而言，这使得PLSE成为一个高风险、高回报的发展故事，而非一个成熟的商业特许经营权。（[pulsebiosciences.com](https://www.pulsebiosciences.com/about-us/?utm_source=openai)） 近期发展强化了公司的临床势头。在2025年和2026年初，Pulse Biosciences 发布了多份季度和年度业务更新，公布了其nPulse心脏导管项目的早期临床数据，并宣布与德克萨斯大学MD安德森癌症中心合作研究nsPFA治疗良性和恶性甲状腺肿瘤。这些更新表明，该公司仍处于证据积累阶段，未来的价值可能取决于临床结果、监管进展和最终的医生采纳。该公司总部仍设在美国，并继续作为一家在纳斯达克上市的医疗技术创新者进行沟通，其目标是将平台扩展到多个治疗领域。（[investors.pulsebiosciences.com](https://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-reports-business-updates-and-fourth-quarter-1?utm_source=openai)）
